- Home
- IOBT vs AVTX Comparison
IOBT vs AVTX Comparison
Compare IOBT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- AVTX
- Stock Information
- Founded
- IOBT 2014
- AVTX 2011
- Country
- IOBT Denmark
- AVTX United States
- Employees
- IOBT N/A
- AVTX N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- AVTX Health Care
- Exchange
- IOBT Nasdaq
- AVTX Nasdaq
- Market Cap
- IOBT 114.6M
- AVTX 138.8M
- IPO Year
- IOBT 2021
- AVTX 2015
- Fundamental
- Price
- IOBT $1.78
- AVTX $10.27
- Analyst Decision
- IOBT Strong Buy
- AVTX Strong Buy
- Analyst Count
- IOBT 2
- AVTX 8
- Target Price
- IOBT $8.00
- AVTX $31.00
- AVG Volume (30 Days)
- IOBT 1.2M
- AVTX 171.6K
- Earning Date
- IOBT 11-11-2025
- AVTX 11-06-2025
- Dividend Yield
- IOBT N/A
- AVTX N/A
- EPS Growth
- IOBT N/A
- AVTX N/A
- EPS
- IOBT N/A
- AVTX N/A
- Revenue
- IOBT N/A
- AVTX $441,000.00
- Revenue This Year
- IOBT N/A
- AVTX N/A
- Revenue Next Year
- IOBT N/A
- AVTX N/A
- P/E Ratio
- IOBT N/A
- AVTX N/A
- Revenue Growth
- IOBT N/A
- AVTX N/A
- 52 Week Low
- IOBT $0.66
- AVTX $3.39
- 52 Week High
- IOBT $2.79
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- IOBT 49.48
- AVTX 53.93
- Support Level
- IOBT $1.71
- AVTX $8.65
- Resistance Level
- IOBT $2.08
- AVTX $12.41
- Average True Range (ATR)
- IOBT 0.15
- AVTX 0.80
- MACD
- IOBT 0.00
- AVTX -0.70
- Stochastic Oscillator
- IOBT 45.45
- AVTX 81.79
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).